Evaluation and Treatment of Failure to Thrive in Fahr's Disease
In a patient with Fahr's disease (primary familial brain calcification) presenting with failure to thrive, immediately evaluate for endocrine abnormalities—particularly hypoparathyroidism and calcium-phosphate metabolism disorders—as these are the primary treatable causes of both conditions and directly impact morbidity and mortality.
Understanding the Clinical Context
Fahr's disease (now termed primary familial brain calcification/PFBC) involves bilateral basal ganglia calcification with motor, cognitive, and psychiatric manifestations 1. When failure to thrive occurs in this context, the evaluation differs fundamentally from typical pediatric or geriatric failure to thrive because the underlying pathophysiology involves phosphate dyshomeostasis and endothelial dysfunction 1.
Diagnostic Evaluation Algorithm
Initial Laboratory Assessment
Obtain these specific tests immediately:
- Serum calcium (total and ionized)
- Phosphate levels
- Parathyroid hormone (PTH)
- Thyroid-stimulating hormone (TSH) and free thyroxine (T4)
- 25-hydroxyvitamin D
- Complete metabolic panel including liver function
- Complete blood count
This targeted approach addresses the metabolic derangements specific to PFBC rather than the broad screening recommended for typical failure to thrive 2.
Secondary Endocrine Evaluation
If initial screening is abnormal or failure to thrive persists:
- IGF-1 and IGF-BP3 for growth hormone assessment
- Morning cortisol
- Prolactin levels
- Consider genetic testing if not already confirmed (SLC20A2, PDGFRB, PDGFB, XPR1, MYORG, JAM2, NAA60) 1
Critical distinction: Unlike the 2026 Pediatrics guideline 2 which recommends minimal testing for typical failure to thrive, Fahr's disease requires focused endocrine evaluation because the disease mechanism directly involves phosphate homeostasis 1.
Nutritional Assessment
- Calculate z-scores for weight-for-length or BMI-for-age (diagnostic if <-1.65 z score) 2
- Assess caloric intake adequacy
- Evaluate for feeding difficulties or dysphagia (neurologic involvement may impair swallowing)
- Screen for malabsorption if gastrointestinal symptoms present
Neurologic Considerations
Document:
- Progression of motor symptoms (may impair feeding ability)
- Cognitive decline affecting self-care
- Psychiatric symptoms (depression, apathy) reducing oral intake
- Medication side effects suppressing appetite
Treatment Approach
Primary Interventions
1. Correct Metabolic Abnormalities:
- Treat hypoparathyroidism if present with calcium and active vitamin D supplementation
- Normalize phosphate levels (critical given PFBC pathophysiology) 1
- Address thyroid dysfunction if identified
2. Nutritional Support:
- Increase caloric density of foods/energy intake 2
- Consider oral nutritional supplementation if dietary modification insufficient 2
- If severe or persistent: nasogastric or gastrostomy tube feeding (used in 40-50% of similar neurogenetic conditions) 3
3. Address Feeding Mechanics:
- Refer for feeding therapy evaluation if swallowing dysfunction suspected 3
- Consider swallowing studies if aspiration risk present
- Treat gastroesophageal reflux with proton pump inhibitors if contributing 3
Ongoing Management
- Monitor growth parameters at every visit (weight, height, head circumference if pediatric) 3
- Regular endocrinology follow-up for metabolic monitoring
- Reassess nutritional status every 3-6 months
- Monitor for progression of neurologic symptoms affecting feeding
Critical Pitfalls to Avoid
Do not apply standard failure to thrive algorithms blindly. The 2026 Pediatrics guideline 2 specifically recommends against extensive testing in typical failure to thrive, but Fahr's disease represents an organic cause requiring targeted metabolic evaluation.
Do not delay endocrine assessment. Hypoparathyroidism and phosphate disorders are both treatable and directly related to PFBC pathogenesis 1.
Do not overlook medication effects. Psychiatric medications commonly used for PFBC behavioral symptoms may suppress appetite.
Do not assume purely nutritional etiology. The progressive neurologic nature of PFBC means functional decline may impair self-feeding or swallowing over time.
When to Escalate Care
Consider hospitalization if:
- Severe electrolyte imbalance (particularly calcium/phosphate) 4
- Acute neurologic deterioration
- Inability to maintain hydration orally
- Weight loss exceeding 10% body weight acutely
The key distinction in managing failure to thrive with Fahr's disease is recognizing that the basal ganglia calcification reflects systemic phosphate-calcium dysregulation 1, making endocrine evaluation and correction the cornerstone of treatment rather than an afterthought.